Prediction of response to Erythropoiesis stimulating agents by erythropoietin level and gene mutations in Low-risk Myelodysplastic syndromes
Not Applicable
Recruiting
- Conditions
- Myelodysplastic syndrome1. Myelodysplastic syndrome2. Erythropoietin level3. Erythropoietin stimulating agent
- Registration Number
- TCTR20200909001
- Lead Sponsor
- Ratchadaphiseksomphot Endowment Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
1. The patient who has diasnosed as Myelodysplastic syndrome during 1 January 2014 ถึง 31 January 2019
2562
2. The patient has age more than 15 years-old
3. IPSS-R score 0-4.5 (MDS low risk)
4. The patient was treated by Erythropoietin stimulating agent
Exclusion Criteria
1. Therapy related MDS
2. History of pure red cell aplasia
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method EPO level After ESA 4-8 weeks Independent two-sample t-test
- Secondary Outcome Measures
Name Time Method Type of Gene mutation After ESA 4-8 weeks Chi square,Size of erythropoietin stimulating agent After ESA 4-8 weeks Mean of Erythropoietin stimulating agent in response group